Abstract

We tested the concept of combining DNA with protein to improve anti-HIV Env systemic and mucosal humoral immune responses. Rhesus macaques were vaccinated with DNA, DNA&protein co-immunization or DNA prime followed by protein boost, and the magnitude and mucosal dissemination of the antibody responses were monitored in both plasma and mucosal secretions. We achieved induction of robust humoral responses by optimized DNA vaccination delivered by in vivo electroporation. These responses were greatly increased upon administration of a protein boost. Importantly, a co-immunization regimen of DNA&protein injected in the same muscle at the same time induced the highest systemic binding and neutralizing antibodies to homologous or heterologous Env as well as the highest Env-specific IgG in saliva. Inclusion of protein in the vaccine resulted in more immunized animals with Env-specific IgG in rectal fluids. Inclusion of DNA in the vaccine significantly increased the longevity of systemic humoral immune responses, whereas protein immunization, either as the only vaccine component or as boost after DNA prime, was followed by a great decline of humoral immune responses overtime. We conclude that DNA&protein co-delivery in a simple vaccine regimen combines the strength of each vaccine component, resulting in improved magnitude, extended longevity and increased mucosal dissemination of the induced antibodies in immunized rhesus macaques.

Highlights

  • DNA is a compelling vaccine vehicle because of its simplicity, scalability, and lack of immunity against the vector

  • We evaluated the magnitude, longevity and mucosal dissemination of humoral immune responses induced in macaques by three vaccine regimens including SIV DNA: DNA only, DNA&Protein co-immunization and DNA prime-protein boost

  • We expanded on these observations with a subsequent study, where we implemented several vaccine improvements, i.e. better env DNA plasmid, inclusion of rhesus IL-12 DNA as adjuvant, improved DNA vaccine delivery by IM injection followed by EP, and the inclusion of protein as a vaccine component

Read more

Summary

Introduction

DNA is a compelling vaccine vehicle because of its simplicity, scalability, and lack of immunity against the vector. HIV/SIV DNA vaccine delivered by IM/EP leads to increased immune responses compared to those induced by conventional needle and syringe injection [9,12,13,14]. In macaques, the combination of such an optimized SIV DNA vaccine regimen delivered by IM/EP led to higher cellular and humoral responses [9,12,20,21,22,23,24] with broader neutralizing activity [20]. Similar improvement in immunogenicity using HIV DNA and IL-12 DNA codelivered by IM/EP has been reported in humans in the recent HVTN 080 trial [7,11], which resulted in the highest response rate in a phase I HIV vaccine trial and indicates that the macaque model has predictive value for human immunogenicity

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call